Autres langues Ribomic Inc.

Actions

4591

JP3974850004

Temps Différé Japan Exchange Autres places de cotation 02:36:02 15/05/2024			Varia. 5j.	Varia. 1 janv.
85 ^JPY	0,00%		+1,19%	-21,30%

13/02	Ribomic Inc. annonce ses résultats pour les neuf mois se terminant le 31 décembre 2023	CI
17/01	Ribomic s'engage dans une collaboration de recherche de médicaments avec Ajinomoto	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Ribomic Inc. announced that it has received ¥4.192212 million in funding from SMBC Nikko Securities Inc.	07/03
Ribomic Inc. announced that it expects to receive ¥4.192212 million in funding from SMBC Nikko Securities Inc.	20/02
Ribomic Inc. Reports Earnings Results for the Nine Months Ended December 31, 2023	13/02
Ribomic and Ajinomoto Co. Partner for Nucleic Acid Aptamer Research	17/01
Ribomic Enters Into Drug Research Collaboration with Ajinomoto	17/01
RIBOMIC Inc. and Ajinomoto Co., Inc. Announce Joint Research Agreement	16/01
RIBOMIC Phase I and II Data Published in the Eye: Full TOFU/RAMEN/TEMPURA Trial Results Demonstrate Clinical Proof of Concept of Umedaptanib Pegol in Exudative Age-Related Macular Degeneration (nAMD)	05/12
RIBOMIC Phase I and II Data Published in the Eye	05/12
Ribomic Inc. Reports Earnings Results for the Half Year Ended September 30, 2023	13/11
Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2024	10/08/23
Ribomic Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	10/08/23
Ribomic Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	12/05/23
Ribomic Inc. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024	12/05/23
Ribomic Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	12/05/23
RIBOMIC, Inc. Announces Start of Administration of RBM-007, Achondroplasia Investigational Drug, to the First Patient in the Early Phase II Study in Japan	28/04/23
Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2023	10/02/23
Ribomic Inc. Reports Earnings Results for the Nine Months Ended December 31, 2022	10/02/23
Ribomic Signs JV MoU for Development of RBM-007 Aptamer in China; Shares Rise 3%	27/12/22
RIBOMIC Announces MOU to Establish Joint Venture for Development of RBM-007 in China	23/12/22
Japan Stocks Buried under Persistent US Monetary Tightening; Eisai Tanks 6% as Alzheimer's Trial Death Count Rises to Two	29/11/22

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Ribomic Inc.

Actions

4591

JP3974850004

Autres langues

Filtres